Purple Biotech to Present New Data On its Oncology Drug NT21

NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...

Related Keywords

San Diego , California , United States , Israel , Rehovot , Hamerkaz , American , Gil Efron , Lior Fhima , Hadas Reuveni , Ras Gtpase , American Association For Cancer Research , Exchange Commission , Bristol Myers Squibb , Online Program Planner , Cancer Research , Company Contact , Clinical Research , Drug Administration , Purple Biotech Ltd , Vp Research , American Association , Chief Executive Officer , Purple Biotech , Molecular Therapeutics , Drug Resistance , Monday Apr , Abstract Number , Predictive Biomarkers , Tuesday Apr , Program Planner , Tumor Associated Antigen , Looking Statements , Safe Harbor , Private Securities Litigation Reform Act , Annual Report , Registration Statements ,